NCT02028065View on ClinicalTrials.gov

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

PHASE1CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

January 3, 2014

Primary Completion Date

July 1, 2014

Study Completion Date

July 1, 2014

Conditions
HypersensitivityAnaphylaxis
Interventions
DRUG

Sugammadex

Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds

DRUG

Placebo

Placebo administered as a single IV bolus over 10 seconds

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02028065 - A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) | Biotech Hunter | Biotech Hunter